Literature DB >> 9874678

Comparison of three different methods for measuring classical pathway complement activity.

T D Jaskowski1, T B Martins, C M Litwin, H R Hill.   

Abstract

The complement system plays an important role in host defense against infection and in most inflammatory processes. The standard 50% hemolytic complement (CH50) assay is the most commonly used method of screening patient sera for functional activity of the classical complement pathway. Our objective in this study was to compare two newer methods (the enzyme immunoassay and the liposome immunoassay) to a commercial CH50 assay for measuring total classical complement activity. We conclude that both newer methods compare well with a CH50 assay and are equally sensitive in screening routine clinical sera.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9874678      PMCID: PMC95674          DOI: 10.1128/CDLI.6.1.137-139.1999

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  12 in total

1.  Complement factor 9 deficiency in serum of human neonates.

Authors:  H A Lassiter; S W Watson; M L Seifring; J E Tanner
Journal:  J Infect Dis       Date:  1992-07       Impact factor: 5.226

Review 2.  Complement deficiencies.

Authors:  H R Colten; F S Rosen
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

3.  Quantitation of the anaphylatoxin C3a in the presence of C3 by a novel sandwich ELISA using monoclonal antibody to a C3a neoepitope.

Authors:  G Zilow; W Naser; R Rutz; R Burger
Journal:  J Immunol Methods       Date:  1989-07-26       Impact factor: 2.303

Review 4.  The Roche Rheumatology Prize Lecture. Complement deficiency and disease.

Authors:  M J Walport
Journal:  Br J Rheumatol       Date:  1993-04

Review 5.  Inherited complement component abnormalities.

Authors:  P H Schur
Journal:  Annu Rev Med       Date:  1986       Impact factor: 13.739

6.  Inherited deficiency of the second component of complement. Rheumatic disease associations.

Authors:  D Glass; D Raum; D Gibson; J S Stillman; P H Schur
Journal:  J Clin Invest       Date:  1976-10       Impact factor: 14.808

Review 7.  Human complement: onset and site of synthesis during fetal life.

Authors:  M Adinolfi
Journal:  Am J Dis Child       Date:  1977-09

8.  The complement system of the newborn infant.

Authors:  J H Drew; C M Arroyave
Journal:  Biol Neonate       Date:  1980

9.  Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex.

Authors:  T E Mollnes; T Lea; S S Frøland; M Harboe
Journal:  Scand J Immunol       Date:  1985-08       Impact factor: 3.487

10.  [Development of the serum levels of complement during the first year of life].

Authors:  C Pedraz; F Lorente; M J Pedraz; V Salazar Villalobos
Journal:  An Esp Pediatr       Date:  1980-07
View more
  11 in total

Review 1.  Modern complement analysis.

Authors:  Michael Kirschfink; Tom E Mollnes
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

Review 2.  To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives.

Authors:  Da Shi; Damian Beasock; Adam Fessler; Janos Szebeni; Julia Y Ljubimova; Kirill A Afonin; Marina A Dobrovolskaia
Journal:  Adv Drug Deliv Rev       Date:  2021-12-10       Impact factor: 15.470

3.  Use of serum or buffer-changed EDTA-plasma in a rapid, inexpensive, and easy-to-perform hemolytic complement assay for differential diagnosis of systemic lupus erythematosus and monitoring of patients with the disease.

Authors:  Kristina N Ekdahl; Dan Norberg; Anders A Bengtsson; Gunnar Sturfelt; Ulf R Nilsson; Bo Nilsson
Journal:  Clin Vaccine Immunol       Date:  2007-03-07

4.  Development of a Sensitive Assay to Screen Nanoparticles in vitro for Complement Activation.

Authors:  Nuzhat Maisha; Tobias Coombs; Erin Lavik
Journal:  ACS Biomater Sci Eng       Date:  2020-07-06

Review 5.  Systematic review of atypical hemolytic uremic syndrome biomarkers.

Authors:  Rupesh Raina; Sidharth K Sethi; Marie-Agnès Dragon-Durey; Amrit Khooblall; Divya Sharma; Priyanka Khandelwal; Ron Shapiro; Olivia Boyer; Hui Kim Yap; Arvind Bagga; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2022-02-03       Impact factor: 3.651

6.  Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice.

Authors:  Yahsou Delmas; Cécile Bordes; Chantal Loirat; Véronique Frémeaux-Bacchi; Christian Combe
Journal:  Clin Kidney J       Date:  2013-04

7.  Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease.

Authors:  Ahmet Ozen; Nurhan Kasap; Ivan Vujkovic-Cvijin; Richard Apps; Foo Cheung; Elif Karakoc-Aydiner; Bilge Akkelle; Sinan Sari; Engin Tutar; Figen Ozcay; Dilara Kocacik Uygun; Ali Islek; Gamze Akgun; Merve Selcuk; Oya Balci Sezer; Yu Zhang; Gunsel Kutluk; Erdem Topal; Ersin Sayar; Cigdem Celikel; Roderick H J Houwen; Aysen Bingol; Ismail Ogulur; Sevgi Bilgic Eltan; Andrew L Snow; Camille Lake; Giovanna Fantoni; Camille Alba; Brian Sellers; Samuel D Chauvin; Clifton L Dalgard; Olivier Harari; Yan G Ni; Ming-Dauh Wang; Kishor Devalaraja-Narashimha; Poorani Subramanian; Rabia Ergelen; Reha Artan; Sukru Nail Guner; Buket Dalgic; John Tsang; Yasmine Belkaid; Deniz Ertem; Safa Baris; Michael J Lenardo
Journal:  Nat Immunol       Date:  2021-01-04       Impact factor: 25.606

Review 8.  Expanding Horizons in Complement Analysis and Quality Control.

Authors:  Ashley Frazer-Abel; Michael Kirschfink; Zoltán Prohászka
Journal:  Front Immunol       Date:  2021-08-09       Impact factor: 7.561

9.  Oversulfated chondroitin sulfate inhibits the complement classical pathway by potentiating C1 inhibitor.

Authors:  Zhao-Hua Zhou; Mohsen Rajabi; Trina Chen; Elena Karnaukhova; Steven Kozlowski
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

10.  Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule.

Authors:  Philippe Gatault; Guillaume Brachet; David Ternant; Danielle Degenne; Guillaume Récipon; Christelle Barbet; Emmanuel Gyan; Valérie Gouilleux-Gruart; Cécile Bordes; Alexandra Farrell; Jean Michel Halimi; Hervé Watier
Journal:  MAbs       Date:  2015-09-04       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.